What's Going On With CNS Pharmaceuticals Stock Tuesday?
What's Going On With CNS Pharmaceuticals Stock Tuesday?
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) shares traded higher initially Tuesday morning but have since reversed following the company's announcement that it entered into an exclusive license agreement with Cortice Biosciences.
CNS Pharmaceuticals公司（納斯達克股票代碼：CNSP）的股票週二早上最初上漲，但在公司宣佈與Cortice Biosciences簽訂獨家許可協議後出現回調。
The Details: CNS secured an exclusive license and the intellectual property rights for TPI 287, a potential treatment for glioblastoma multiforme (GBM).
細節：CNS獲得了TPI 287的獨家許可和知識產權，這是一種治療根治性多形性膠質母細胞瘤（GBM）的潛在療法。
CNS will pay Cortice 616, 698 shares of the company's common stock in exchange for the license and intellectual property rights. In addition, there are possible future success-dependent milestone payments of cash or the company's common stock
CNS將向Cortice支付616,698股公司普通股以換取許可和知識產權。此外，還有可能基於未來成就而支付現金或公司普通股的里程碑款項。
A multicenter Phase 1 study of TPI 287 combined with bevacizumab in recurrent GBM patients showed a progression-free survival (PFS) of 5.5 months and an overall survival (OS) of 13.4 months. In comparison, bevacizumab alone or with chemotherapy showed a PFS of 2-4 months and an OS of 6-9 months.
TPI 287聯合貝伐單抗治療複發性GBM的多中心1期研究顯示，無進展生存期(PFS)爲5.5個月，總生存期(OS)爲13.4個月。相比之下，貝伐單抗單獨或聯合化療的PFS爲2-4個月，OS爲6-9個月。
CNS believes that another one of its drug candidates for the treatment of GBM, Berubicin, could serve as an ideal complementary asset to TPI 287.
CNS認爲，其治療GBM的另一種藥物候選者Berubicin可以作爲TPI 287的理想補充資產。
John Climaco, CEO of CNS Pharmaceuticals, stated, "For years, our team has searched for another drug candidate with the same high level of human data-supported therapeutic potential in GBM as Berubicin. The in-licensing of TPI 287 is a transformational step forward and we are prepared for the next stage to execute our vision of CNS Pharmaceuticals being the leading biopharma company developing drugs for this devastating and currently inescapably fatal disease."
CNS Pharmaceuticals的首席執行官John Climaco表示：“多年來，我們的團隊一直在尋找另一個藥物候選者，在GBm方面具有與Berubicin相同的高水平的人體數據支持的治療潛力。內部許可TPI 287是邁向變革性的重要一步，我們已準備好執行我們的願景，使CNS Pharmaceuticals成爲開發治療這種可怕且目前無法逃脫致命疾病的生物製藥公司的領先企業。”
The company intends to consult with the U.S. FDA to receive feedback on the design of a study aimed at registering TPI 287 for recurrent GBM, with plans to start the study in 2025.
該公司打算與美國FDA諮詢，以獲得有關設計旨在註冊TPI 287用於複發性GBm的研究的反饋意見，並計劃在2025年開始該研究。
Related Link: Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
相關鏈接：專家展望：14位分析師看Sage Therapeutics
CNSP Price Action: At the time of publication, CNS shares are trading 60% lower at 41 cents, per data from Benzinga Pro.
CNS公司(CNS)股價在發佈時下跌了60%，收於41美分，根據Benzinga Pro的數據。
Image: Myriams-Fotos from Pixabay
圖片：來自Pixabay的Myriams-Fotos
.
.